Editors for Cancer Biology

We aim to publish conceptually important advances in all areas of cancer biology, including the discovery of new mechanisms responsible for cancer initiation, progression and therapy response. We are also interested in clinical trials or other clinical observations that reveal new and important biological insights. Read the latest research in this subject area.

Type

All sections

eLife's peer-review process is changing. From January 2023, eLife will no longer make accept/reject decisions after peer review. Instead, every preprint sent for peer review will be published on the eLife website as a “Reviewed Preprint” that includes an eLife assessment, public reviews, and a response from the authors (if available). When writing the eLife assessment, the editors and reviewers will use a common vocabulary to summarize the significance of the findings and the strength of the evidence reported in the preprint. Read about the new process.

Senior editors

Utpal Banerjee

University of California, Los Angeles, United States

Utpal Banerjee is the Irving and Jean Stone Professor and Chair of the Department of Molecular, Cell and Developmental Biology at the University of California, Los Angeles, with a joint appointment in the Department of Biological Chemistry at the David Geffen School of Medicine. He also serves as Co-Director of the Broad Stem Cell Research Center and as Director of the UCLA Interdepartmental Minor in Biomedical Research. He is a member of UCLA’s Jonsson Comprehensive Cancer Center and is affiliated with the Brain Research Institute and the Neuroscience Graduate Program.

Banerjee’s laboratory has worked on several oncogenic and metabolic signals that are important in development and disease. The lab studies the effects of systemic signals on the maintenance of blood progenitors in Drosophila, and the role of metabolic pathways in the control of proliferation and differentiation in the preimplantation mouse embryo.

Expertise
Developmental Biology
Stem Cells and Regenerative Medicine
Cancer Biology

Research focus
haematopoiesis
cancer biology

Experimental organism
D. melanogaster
mouse
Wafik S El-Deiry

Brown University, United States

Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director, Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown and Lifespan. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He sees patients in his weekly clinic at Rhode Island Hospital focused on care of patients with colorectal cancer and participates in clinical trials based on his laboratory’s research on novel therapeutics. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014 Dr El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He was previously a tenured Professor of Medicine (Hematology-Oncology), Genetics, and Pharmacology at University of Pennsylvania, co-Leader of the Radiobiology and Imaging Program at the Abramson Cancer Center and Associate Director for Physician-Scientist Training in Hematology-Oncology when he left Penn in 2010. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. As a practicing academic Oncologist, his scientific interest and expertise is in cell death, drug resistance in cancer and drug discovery and development. El-Deiry founded two companies, Oncoceutics, Inc. and p53-Therapeutics, Inc.

El-Deiry discovered p21(WAF1) as a p53 target gene, universal cell cycle inhibitor, and tumor suppressor gene that for the first time explained the mammalian cell stress response. He discovered TRAIL receptor DR5 and its regulation by p53. TRAIL is part of the host immune system that suppresses cancer and its metastases. His lab created a knock-out mouse for TRAIL receptor DR5 and this mouse is tumor prone and develops an inflammatory syndrome in the lungs and gut after sub-lethal irradiation. He identified c-Myc as a major determinant of TRAIL sensitivity and demonstrated synergy between TRAIL therapy and multi-kinase inhibitor sorafenib. Building on his prior accomplishments, El-Deiry discovered ONC201/TIC10 as a first-in-class TRAIL pathway inducer that is orally bioavailable and crosses the blood-brain barrier to treat brain tumors. TRAIL and Foxo3a are required for the anti-tumor effect of ONC201 through dual blockade of ERK and Akt kinases that promotes the nuclear translocation of the Foxo3a transcription factor which directly regulates the TRAIL gene. Data from El-Deiry’s lab identified that ONC201 induces TRAIL receptor DR5 through an integrated stress response involving ATF4 and CHOP transcription factors. Patients with among the most aggressive gliomas (H3K27M mutant DIPG) have had exceptional responses to ONC201.

As a physician-scientist, Dr El-Deiry has worked to bring new discoveries to the clinic. He is committed in the next phase of his career to unraveling the mechanisms involved in p53 pathway restoration by candidate therapeutics his lab has discovered. This is exciting as he is defining a novel class of anti-cancer drugs with p53 pathway restoration and S-phase checkpoint targeting and recognizing ATF4 as a major transcription factor mechanism for p53 pathway restoration in p53-null or p53 mutant tumor cells. He is establishing transcriptomic and proteomic data sets with chemotherapy that acts through p53, and with novel small molecules that restore the p53 pathway in p53-deficient or mutant p53 expressing cells. He is exploiting medicinal chemistry and organoid technologies to perform his translational science that is leading to clinical trials some of which he leads. Dr El-Deiry conducts basic and translational clinical oncology therapeutics research through funded NIH grants, Foundations and industry. He is a member of the ASCI, AAP, Past President of the Interurban Clinical Club, previous Chair of ASCO’s Tumor Biology Track, and past Chair of an NIH Study Section on Cancer Therapeutics. Dr El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.

Expertise
Medicine
Cancer Biology

Research focus
cancer
tumor suppressor genes
colorectal cancer
p53 pathway
cell death
medical oncology
drug development
drug discovery
p21(WAF1)
ONC201/TIC10
physician-scientist issues

Experimental organism
human
mouse

Competing interests statement
Dr El-Deiry receives funding from the NIH/NCI, the Warren Alpert Foundation, and D&D Pharmatech. He is a Specialty Chief Editor for the Cancer Molecular Targets and Therapeutics Section of Frontiers in Oncology. He is also a Section Editor for Molecular Oncology and HemOnc Today. Dr El-Deiry is the scientific founder and shareholder of Oncoceutics, Inc. and p53-Therapeutics, Inc.
Eduardo Franco

McGill University, Canada

Eduardo Franco is Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. He holds BSc (1975) and Licentiate (1976) degrees in biology from Universidade de Campinas, Brazil, and master's (MPH) and doctoral (DrPH) degrees in public health microbiology from the University of North Carolina at Chapel Hill (1981-84). He was a Guest Researcher at the US Centers for Disease Control in Atlanta (1980-81 and 1983-84), and a post-doctoral fellow in cancer epidemiology during 1984 at the International Agency for Research on Cancer in Lyon, France, at the US National Cancer Institute (NCI) in Bethesda, and at Louisiana State University, in New Orleans. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award, Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society, the Women in US Government’s Leadership Award, the Canadian Cancer Society’s Warwick Prize, the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics, the University of British Columbia’s Chew Wei Memorial Prize in Cancer Research, and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He has mentored 115 graduate students and post-doctoral fellows, and 30 undergraduate trainees. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. Heholds an honorary doctorate from Universidade Fernando Pessoa, Porto, Portugal.

Expertise
Cancer Biology
Epidemiology and Global Health
Medicine

Research focus
cancer epidemiology
cancer prevention
human papillomavirus
cancer screening

Experimental organism
human

Competing interests statement
Entire research program funded by the Medical Research Council of Canada (until 1999), Canadian Institutes of Health Research (CIHR) (1999-present), National Institutes of Health, Canadian Cancer Society, and Cancer Research Society. He has received salary awards from the Fonds de Recherche Quebec Santé and CIHR. He holds a James McGill Professorship and the Minda de Gunzburg Endowed Chair at McGill University. He serves as Editor-in-Chief for Preventive Medicine and Preventive Medicine Reports and serves on the editorial boards of Cancer Epidemiology, Biomarkers & Prevention, International Journal of Cancer, Papillomavirus Research, and Salud Publica de Mexico. He has served as occasional consultant to companies involved with HPV vaccination (Merck and GSK) and HPV diagnostics (Roche, Abbott, Qiagen, and BD).
Erica Golemis

Fox Chase Cancer Center, United States

Erica A Golemis, PhD is a Professor at Fox Chase Cancer Center (FCCC), and Adjunct Professor at the Temple University School of Medicine, the University of Pennsylvania, and the Drexel University College of Medicine. Since 2008, she has served as Co-Leader for the FCCC Molecular Therapeutics program, and as Deputy Chief Science Officer at FCCC. She is an elected Fellow of the American Association for the Advancement of Science, and holds the William Wikoff Smith Chair in Biology at Fox Chase. Dr Golemis joined FCCC in 1993, after completing graduate training in mechanisms of leukemogenesis at MIT, and postdoctoral work at Harvard Medical School and Massachusetts General Hospital leading to the development of new technology for the identification and analysis of protein interaction networks. One focus of her reserch is the targeted study of a group of oncogenes including NEDD9, AURKA, and associated proteins that regulate cell cycle and metastasis; this work has recently focused on defining non-canonical activities of these proteins in control of ciliation as a mechanism for their oncogenic effect. A second research area is the use of bioinformatics-guided and siRNA screening approaches to elucidate signaling networks that can be targeted to improve therapeutic response; this work is typically highly collaborative with clinical researchers. In the past 25 years, she has served continuously on peer-review panels for the NIH, the American Cancer Society, the DOD, the Komen Foundation, and other agencies.

Expertise
Cancer Biology
Cell Biology

Research focus
signal transduction
targeted therapy
mitosis
cilia
polycystic kidney disease
colorectal cancer
head and neck cancer
invasion
metastasis

Competing interests statement
Dr Golemis currently receives funding from the National Institutes of Health (NIH) and holds editorial roles at the following journals: Cancer Biology and Therapy, Frontiers in Oncology, Gene and BMC Cancer.
Caigang Liu

Shengjing Hospital of China Medical University, China

Caigang Liu received his PhD from the China Medical University, and trained clinically at first hospital of China Medical University. Then joined and served as a director of Breast Center Shengjing Hospital of China Medical University in 2016. His current research interests focus on clinical and translational research of oncology. In recent years, he has led a clinical research term to explore the improvement in breast reconstruction surgery and highly safe and effective anti-cancer strategies, along with identification of therapeutic targets and development of small molecular drugs against cancer metastasis. He has led several projects funded by the National Natural Science Foundation, including the discovery of FSIP1 as a new target for anti-HER2 treatment, and is developing a new strategy to reverse anti-HER2 resistance in breast cancer. He is a member of the National Micro-noninvasive Committee of Chinese Medical Association, a vice chairman of the first breast disease branch of China Sexology Association, and a member of the Standing Committee in breast cancer marker collaboration group of Chinese Anti-cancer Association.

Expertise
Medicine
Cancer Biology

Research focus
surgical oncology
oncological clinical trials
breast cancer translational medicine
cancer metastasis and drug resistance
small molecular drug development

Experimental organism
human
mouse

Competing interests statement
Caigang Liu is currently funded by the National Natural Science Foundation of China and “Top young talent” project of Liaoning province, China. He now holds a number of patents for anti-tumor small molecular drugs and Traditional Chinese Medicine.
Shlomo Melmed

Cedars-Sinai Medical Center, United States

Shlomo Melmed MD's career has focused on integrating basic science discovery with prospective study of patients with pituitary disease. He has trained more then 70 pre- and post-doctoral trainees. His laboratory is at the forefront of pituitary discovery, focusing on the study of the pathogenesis and treatment of pituitary tumors. Fundamental discovery achievements include elucidating intrapituitary signaling mechanisms underlying excess tumor-derived GH, ACTH or PRL secretion; identification of novel subcellular therapeutic targets for drug application in clinical trials; understanding the relationship between tumor cell proliferation and GH hypersecretion and peripheral GH actions. Dr Melmed and colleagues have applied these findings to understanding cell cycle mechanisms underlying the extraordinarily rare transformation of these invariably benign adenomas to malignancy. They have coupled these translational discoveries with leading scholarly roles in developing clinical guidelines, pivotal investigator-initiated clinical trials, and original disease classification for pituitary medicine.

Expertise
Medicine
Cancer Biology

Research focus
endocrinology
pituitary medicine
endocrine tumors

Competing interests statement
Shlomo Melmed MD edits The Pituitary, and co-edits the Williams Textbook of Endocrinology; he is Editor-in-Chief of Pituitary and post-Editor-in-Chief of Endocrinology. He was President of the Pituitary Society, and of International Society of Endocrinology and is a director of the California Institute of Regenerative Medicine. His laboratory is funded by the NIH.
Tony Ng

King's College London, United Kingdom

Tony Ng (FMEDSCI, MB ChB, MRCP, FRCPath, PhD) brings a rich spectrum of knowledge and capabilities with clinical experience in treating AIDS patients (with opportunistic infections and cancers) and fundamental immunology skills. He is also a pioneer of molecular imaging in cancer. He was the first person to use antibody based fluorescence lifetime imaging (FLIM) approaches in tumour cells and tissues to monitor protein states and function. He has published on how to visualize protein biochemistry in preclinical models; as well as in patient-derived cancer tissues for establishing in vitro/ companion diagnostics. He has adopted a multidisciplinary approach to understand cancer recurrence and also to stratify molecularly targeted agents in combination with immunotherapy. His research bridges the gap between physics, biology and medicine, particularly in the field of translational cancer research.

For clinical translation, he has the proven ability to coordinate and work cooperatively with colleagues and leaders in a wide variety of disciplines (imaging, cell biology, oncology, bioinformatics, surgery, pathology, genomics, as well as physical science disciplines such as mathematics, physics, chemistry and engineering). He has directed the KCL and UCL Comprehensive Cancer Imaging Centre (CCIC, one of four centres funded by CRUK & EPSRC in the UK) since its inception in 2008. The vision for the CCIC is to develop novel imaging (PET and MRI) technologies and use them in combination with clinicopathological assessment, genomics and in-house nanoscopic imaging to measure protein interactions in the context of interventional trials. In such trial context, the tissue imaging (FLIM histology) approach he has developed and refined over the years is beginning to reveal ErbB/ HER receptor rewiring as a mechanism of resistance in human tumours under selection pressure such as cetuximab.

Tony Ng is the current Director of the Comprehensive Cancer Centre, part of the KCL School of Cancer & Pharmaceutical Sciences, and the National Institute for Health and Care Research (NIHR) Guy’s & St Thomas’ Biomedical Research Centre (BRC) Cancer Theme. In 2022, he joined GSK on a part-time basis, to help establish the GSK-KCL Translational Oncology Research Hub which was which was announced in September 2021. The aim is to apply his clinical medicine training as well as immunology, biochemistry and imaging expertise to accelerate the development of the anti-cancer drugs. HIs experience of collaborating with mathematicians/theoretical physicists creates an opportunity to bridge the biology & AI/ML interface, an essential component of delivering the innovative Digital biological twin vision.

Training/expertise: Medicine, Immunology, Cancer cell biology, Biochemistry and Optical Imaging/Biophysics as well as preclinical Radionuclide imaging.

Expertise
Medicine
Cancer Biology
Immunology and Inflammation

Research focus
imaging
biomarkers
trial
immune
cancer
reverse translation
exosome
organoid
tumour microenvironment

Competing interests statement
At KCL, Tony Ng receives funding from Cancer Research UK, Medical Research Council, Wellcome Leap Inc., European Commission and GSK. He is employed on a part time basis as the Vice President of the Digital biological twin Unit at GSK.
Päivi Ojala

University of Helsinki, Finland
Imperial College London, United Kingdom

Päivi Ojala is the Professor of Cancer Cell Biology at University of Helsinki and Chair of Viral Tumorigenesis at Imperial College London. She has made significant contributions to the Kaposi’s Sarcoma herpesvirus (KSHV) field and has more recently focused also on the role of lymphatic endothelial microenvironment on cancer cell metastasis. She has expertise in organotypic 3D co-culture models, cell-based high-content screens, protein kinase signalling and viral technologies. Her work has led to demonstration of restoration of p53 function by small molecule inhibitors as a therapeutic modality for KSHV-induced lymphomas, identification of host Pim kinases, nucleophosmin, and the p53-p21 axis as novel regulators of viral replication, and shown that KSHV infection reprograms lymphatic endothelial cells (LECs) to a new, more invasive cell type. They have also demonstrated that LEC interaction with melanoma cells leads to increased distant organ metastasis in vivo, which is dependent on MMP14, Notch3 and b1-integrin- Dr. Ojala holds a doctoral degree in Molecular Genetics from the University of Helsinki, and has received postdoctoral training at the Yale School of Medicine, CT, USA.

Expertise
Cancer Biology
Microbiology and Infectious Disease

Research focus
human tumor viruses
virus-host interactions
cancer metastasis
notch signaling
lymphatic endothelial transcription factors
CAR T cell therapies

Experimental organism
human primary and cancer cells
immunocompromised mouse

Competing interests statement
Päivi Ojala receives funding from the Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland and University of Helsinki.
W Kimryn Rathmell

Vanderbilt University Medical Center, United States

Dr Kimryn Rathmell is the Chair of Medicine and Physician-in-Chief at Vanderbilt University Medical Center. She is a physician-scientist studying the molecular biology of renal cell carcinomas and rare tumors of the kidney. She earned her MD and PhD in Biophysics at Stanford University. She completed internal medicine training at the University of Chicago and the University of Pennsylvania, and fellowship in medical oncology at the University of Pennsylvania. She joined Vanderbilt in 2015 to lead the Division of Hematology and Oncology.

Her research program focuses on understanding the molecular pathogenesis of renal cell carcinomas and spans early models of renal tumorigenesis, novel imaging strategies for diagnosis and screening of kidney cancer, epigenetic regulation of kidney cancers, metabolic features of tumorigenesis, and novel therapeutic strategies to overcome resistance to anti-angiogenic therapy and checkpoint targeted immunotherapy. With these bench to bedside strategies, her laboratory endeavors to integrate knowledge of pathways that promote cancer development with translational clinical studies, and uses these discoveries to develop robust approaches to improve the survival of patients with kidney cancers. She serves as the Deputy Director for Research Integration and Career Development for the Vanderbilt-Ingram Cancer Center and on the Board of Scientific Advisors for the National Cancer Institute.

Expertise
Cancer Biology
Medicine

Research focus
cancer biology
molecular biology
epigenetics
biomarkers
angiogenesis

Competing interests statement
Stock and Other Ownership Interests
Company: Sitryx (Recipient: An Immediate Family Member); Company: Caribou Publishing (Recipient: An Immediate Family Member); Company: Nirogy Therapeutics (Recipient: An Immediate Family Member)Honoraria
Company: Merck (Recipient: An Immediate Family Member); Company: Pfizer (Recipient: An Immediate Family Member)Consulting or Advisory Role
Company: Sitryx (Recipient: An Immediate Family Member); Company: caribou Biosciences (Recipient: An Immediate Family Member)Research Funding
Company: Incyte (Recipient: An Immediate Family Member); Company: Calithera Biosciences (Recipient: An Immediate Family Member); Company: Tempus (Recipient: An Immediate Family Member); Company: Peloton Therapeutics (Recipient: Institution); Company: Pfizer (Recipient: Institution); Company: Genentech (Recipient: Institution); Company: E.R. Squibb Sons, LLC (Recipient: Institution)Patents, Royalties, Other Intellectual Property
ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapyOpen Payments Link
Richard M White

Memorial Sloan Kettering Cancer Center, United States

Richard White, M.D., Ph.D, is a physician-scientist at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interested in basic mechanisms underlying metastasis, using the zebrafish as a model system. His work has established numerous techniques for cancer modeling and high-resolution imaging in the fish. Using these tools, the lab is focused on the cross-talk between tumor cells and the microenvironment, and how this interplay influences metastatic success. His work has revealed novel interactions between melanoma cells and adipocytes in the microenvironment, and how neural crest programs play roles in melanoma progression. He has been awarded the NIH Director’s New Innovator Award, the Pershing Square Foundation Award, and the Mark Foundation ASPIRE award.

Expertise
Cancer Biology
Cell Biology
Developmental Biology
Medicine

Research focus
development
neural crest
zebrafish
cancer
melanoma
metastasis
microenvironment

Experimental organism
zebrafish

Competing interests statement
Richard White receives funding from the National Institutes of Health, the Pershing Square Sohn Foundation, the Mark Foundation, the Melanoma Research Alliance, the American Cancer Society and the Harry J. Lloyd Foundation. He receives consulting fees from N-of-One, Inc.

Reviewing editors

Nicola Aceto

Swiss Federal Institute of Technology in Zurich, Switzerland

Expertise
Cancer Biology

Research focus
disseminated tumor cells
circulating tumor cells
cancer progression
metastasis
Wadih Arap

Rutgers Cancer Institute of New Jersey at University Hospital, United States

Expertise
Medicine
Cancer Biology

Research focus
clinical oncology
genitourinary (GU) cancers
prostate cancer
Robert Baiocchi

The Ohio State University, United States

Expertise
Medicine
Cancer Biology
Immunology and Inflammation

Research focus
Epstein Barr Virus
lymphoma
cancer therapeutics
cancer vaccines
cancer immunology
cancer immunotherapy
cancer epigenetics
Muthuswamy Balasubramanyam

ICMR Emeritus Scientist, Madras Diabetes Research Foundation, India

Expertise
Medicine
Biochemistry and Chemical Biology
Cancer Biology
Cell Biology
Developmental Biology
Epidemiology and Global Health
Genetics and Genomics
Immunology and Inflammation
Neuroscience
Stem Cells and Regenerative Medicine

Research focus
disease biology
diabetes
aging
omnics
calcium signaling
endocrine disruptors
probiotics
molecular medicine
Nicholas Banovich

Translational Genomics Research Institute (TGen), United States

Expertise
Cancer Biology
Genetics and Genomics
Chromosomes and Gene Expression

Research focus
single cell biology
CAR T cell therapy
gene regulation
pulmonary fibrosis
quantitative trait loci
Frederic A Bard

Institute of Molecular and Cell Biology (A*STAR), Singapore

Expertise
Cell Biology
Cancer Biology

Research focus
Golgi
protein glycosylation
signaling
cancer
matrix degradation
cell migration

Experimental organism
human
mouse
Anton M Bennett

Yale University, United States

Expertise
Cell Biology
Biochemistry and Chemical Biology
Cancer Biology

Research focus
cell signalling
metabolism
protein tyrosine phosphorylation
protein tyrosine kinases
protein tyrosine phosphatases
Philip Boonstra

University of Michigan, United States

Expertise
Medicine
Epidemiology and Global Health
Cancer Biology
Genetics and Genomics

Research focus
biostatistics
clinical trials
cancer biostatistics
epidemiology
ECMO
statistical programming
Dirce M Carraro

AC Camargo Cancer Center, Brazil

Expertise
Medicine
Cancer Biology

Research focus
oncology
cancer genomics
Nyasha Chambwe

St Jude Children's Research Hospital, United States

Expertise
Cancer Biology
Computational and Systems Biology
Genetics and Genomics

Research focus
bioinformatics
computational biology
cancer genomics
population genomics
data analysis

Experimental organism
human
Jungmin Choi

Korea University College of Medicine, South Korea

Expertise
Cancer Biology
Computational and Systems Biology
Genetics and Genomics
Medicine

Research focus
rare disorders
single cell genomics
computational biology
human genomics
Leslie D Cope

Johns Hopkins University, United States

Expertise
Cancer Biology
Computational and Systems Biology
Genetics and Genomics

Research focus
bioinformatics
biostatistics
high-throughput genomic data
methods for identifying and validating biomarkers
Seth J Corey

Cleveland Clinic, United States

Expertise
Cancer Biology
Medicine

Research focus
myeloid malignancies
inherited or acquired bone marrow failure
neutrophils
platelets zebrafish
cancer evolution
proteostasis
Maximiliano A D'Angelo

Sanford Burnham Prebys Medical Discovery Institute, United States

Expertise
Cancer Biology
Cell Biology
Immunology and Inflammation

Research focus
nuclear pore complex
nuclear transport
importin
exportin
immunology
cancer
muscle
Yamini Dalal

National Cancer Institute, United States

Expertise
Cancer Biology
Chromosomes and Gene Expression
Genetics and Genomics

Research focus
chromatin
centromeres
chromosomes
mitosis
chromosome cancer biology
histone variants
nucleosomes

Experimental organism
human
mouse
Irwin Davidson

Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/UDS, France

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Chromosomes and Gene Expression

Research focus
transcription
chromatin
genomics
cancer

Experimental organism
human
mouse
Roger J Davis

University of Massachusetts Medical School, United States

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Cell Biology

Research focus
diabetes
NAFLD
NASH
metabolism
insulin resistance
cancer
signal transduction

Experimental organism
mouse
human
Emek Demir

Oregon Health and Science University, United States

Expertise
Cancer Biology
Computational and Systems Biology
Genetics and Genomics
Medicine

Research focus
proteomics
Gina M DeNicola

Moffitt Cancer Center, United States

Expertise
Cancer Biology
Biochemistry and Chemical Biology

Research focus
tumor metabolism
redox biology
ROS
sulfur metabolism
NRF2/KEAP1
mouse models of cancer
Ivan Dikic

Goethe University Frankfurt, Germany

Expertise
Biochemistry and Chemical Biology
Cell Biology
Cancer Biology
Microbiology and Infectious Disease

Research focus
ubiquitination
autophagy
ER remodelling
infection
virus
bacteria
cancer

Experimental organism
mouse
C. elegans
S. cerevisiae
Martin Eilers

University of Würzburg, Germany

Expertise
Cancer Biology

Research focus
Myc proteins
Myc function
Targeting N-MYC/AURORA for tumor therapy
Myc and Ubiquitin

Experimental organism
human
Eduardo Eyras

Australian National University, Australia

Expertise
Genetics and Genomics
Cancer Biology
Chromosomes and Gene Expression
Computational and Systems Biology

Research focus
bioinformatics
transcriptomics
long-read sequencing technologies
RNA splicing
alternative splicing
nanopore
Lydia W S Finley

Memorial Sloan Kettering Cancer Center, United States

Expertise
Cell Biology
Cancer Biology
Stem Cells and Regenerative Medicine

Research focus
cell metabolism
cancer
stem cells
epigenetics
cell fate
Stacey D Finley

University of Southern California, United States

Expertise
Medicine
Computational and Systems Biology
Cancer Biology

Research focus
mathematical modeling
multiscale models
biochemical signal transduction networks
Margaret Frame

University of Edinburgh, United Kingdom

Expertise
Cancer Biology

Research focus
cancer
cell adhesion networks
nodal tyrosine kinases
Yogesh K Gupta

The University of Texas Health Science Center at San Antonio, United States

Expertise
Medicine
Structural Biology and Molecular Biophysics
Cancer Biology
Microbiology and Infectious Disease

Research focus
drug discovery
nucleic acid modifications
cancer epigenetics
structures of viral proteins
host-pathogen interactions
William C Hahn

Dana-Farber Cancer Institute, United States

Expertise
Cancer Biology
Genetics and Genomics
Medicine

Research focus
cancer
transformation
functional genomics
RAS
YAP1

Experimental organism
human
Elizabeth P Henske

Brigham And Women's Hospital, United States

Expertise
Medicine
Cancer Biology

Research focus
tuberous sclerosis complex
lymphangioleiomyomatosis
mTOR
prostate cancer
Ping-Chih Ho

Ludwig Institute for Cancer Research, Switzerland

Expertise
Cancer Biology
Immunology and Inflammation
Cell Biology

Research focus
immunometabolism
cancer immunology
tumor microenvironment
immunotherapy
adaptive immunity
macrophages
metabolic disease

Experimental organism
mouse
Wenwei Hu

Rutgers University, United States

Expertise
Cancer Biology

Research focus
p53 signaling
tumor suppressors
cancer metabolism
cancer cell biology
signal transduction

Experimental organism
human
mouse
Tony Hunter

Salk Institute for Biological Studies, United States

Expertise
Cancer Biology
Cell Biology

Research focus
cancer
signal transduction
phosphorylation
ubiquitylation
sumoylation

Experimental organism
mouse
yeast
Arezu Jahani-Asl

McGill University, Canada

Expertise
Cancer Biology
Cell Biology
Developmental Biology

Research focus
glioblastoma
stem cells
mitochondria
transcription
mental retardation
neurodegeneration
cancer

Experimental organism
mouse
Jae-Wook Jeong

University of Missouri – Columbia, United States

Expertise
Medicine
Cancer Biology

Research focus
estrogen
endometriosis
uterus
endometrium
endometrial cancer
implantation
decidualization
progesterone
Jean Jiang

The University of Texas Health Science Center at San Antonio, United States

Expertise
Medicine
Cell Biology
Cancer Biology

Research focus
gap junctions
hemichannels
connexins
bone biology
osteocyte
bone mechanobiology
cancer bone metastasis
lens biology
John Kopchick

Ohio University, United States

Expertise
Cancer Biology
Medicine
Chromosomes and Gene Expression

Research focus
molecular mechanisms of aging
fibrosis
growth hormone
growth hormone receptor antagonists
IGF-1
Acromegaly
Ashish Lal

National Institutes of Health, United States

Expertise
Cancer Biology
Biochemistry and Chemical Biology
Chromosomes and Gene Expression
Genetics and Genomics

Research focus
RNA biology
lncRNAs
microRNAs
gene regulation
cancer biology
p53

Experimental organism
human
Beate Lichtenberger

Medical University of Vienna, Austria

Expertise
Cancer Biology
Stem Cells and Regenerative Medicine

Research focus
Cancer-associated fibroblasts (CAFs)
fibroblast-mediated skin pathologies
skin cancer
stem cell fate decisions

Experimental organism
human
mouse
Huiping Liu

Northwestern University, United States

Expertise
Medicine
Cancer Biology

Research focus
cancer stem cells
circulating tumor cells
exosome
cancer immunity
metastasis
breast cancer
Yuting Ma

Suzhou Institute of Systems Medicine, China

Expertise
Cancer Biology
Immunology and Inflammation
Cell Biology

Research focus
tumor immunology
immunotherapy
tumor microenvironment
stress responses
neuroendocrine-immune crosstalk
cell death
Kay F Macleod

University of Chicago, United States

Expertise
Cell Biology
Cancer Biology

Research focus
autophagy
mitochondria
pancreatic cancer
breast cancer
liver homeostasis
tumor metabolism

Experimental organism
mouse
human
Jean-Christophe Marine

Vlaams Instituut voor Biotechnologie, Belgium

Expertise
Cancer Biology
Genetics and Genomics

Research focus
mouse genetics
molecular oncology
cancer genomics

Experimental organism
mouse
Rui Medeiros

Instituto Português de Oncologia-Porto, Portugal

Expertise
Medicine
Cancer Biology

Research focus
oncology
molecular oncology
viral pathology
Simón Méndez-Ferrer

University of Cambridge, United Kingdom

Expertise
Stem Cells and Regenerative Medicine
Developmental Biology
Cancer Biology
Medicine

Research focus
haematopoietic stem cell niche
mesenchymal stem cells
myeloproliferative neoplasms
acute myeloid leukemia
neuroimmunology
Goutham Narla

University of Michigan, United States

Expertise
Medicine
Cancer Biology
Genetics and Genomics

Research focus
cancer therapeutics
cancer genetics
small molecule drug development
protein phosphatase

Experimental organism
human
mouse
Maddy Parsons

King's College London, United Kingdom

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Cell Biology
Physics of Living Systems

Research focus
adhesion
migration
cytoskeleton
receptor signalling
extracellular matrix
fibrosis
cancer

Experimental organism
mouse
Renata Pasqualini

Rutgers University, United States

Expertise
Medicine
Cancer Biology

Research focus
radiation oncology
translational cancer research
prostate cancer
vascular biology
Lynne-Marie Postovit

University of Alberta, Canada

Expertise
Cancer Biology
Cell Biology
Stem Cells and Regenerative Medicine

Research focus
cellular plasticity
tumour microenvironment
hypoxia
stem cells
metastasis
ovarian cancer
breast cancer
Michaela Reagan

Maine Medical Center Research Institute, United States

Expertise
Medicine
Cancer Biology
Cell Biology
Stem Cells and Regenerative Medicine

Research focus
multiple myeloma
bone marrow adipocyte
fatty acid binding protein
cancer-induced bone disease
osteolysis

Experimental organism
mouse
Natalia Rubinstein

University of Buenos Aires-CONICET, Argentina

Expertise
Cancer Biology
Immunology and Inflammation
Medicine
Stem Cells and Regenerative Medicine

Research focus
breast cancer tumor cell
molecular biology
drug resistance
tumor immunology
Alejandro San Martín

Centro de Estudios Científicos, Chile

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Cell Biology

Research focus
imaging
metabolism
FRET
single-fluorophore
single-cell
cell physiology
optogenetics
Charles Sawyers

Memorial Sloan-Kettering Cancer Center, United States

Expertise
Cancer Biology
Medicine

Research focus
translational medicine
oncology

Experimental organism
human
Ernestina Schipani

University of Pennsylvania, United States

Expertise
Medicine
Stem Cells and Regenerative Medicine
Cell Biology
Developmental Biology
Cancer Biology

Research focus
hypoxia
hypoxia-inducible factors
mitochondria
skeleton
chondrocytes
bone
G protein-coupled receptors (GPCR)
Katharina Schlacher

UT MD Anderson Cancer Center, United States

Expertise
Cancer Biology
Chromosomes and Gene Expression

Research focus
mitochondria
mitochondrial DNA replication
mitochondrial instability
cGAS
inflammation
inflammation signaling
inflammasome
Fanconi Anemia
Nima Sharifi

Cleveland Clinic, United States

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Medicine

Research focus
steroid biochemistry
steroid metabolism
prostate cancer
nuclear receptors
hormone therapy resistance
androgens
oncology

Experimental organism
mouse
Margaret Stanley

University of Cambridge, United Kingdom

Expertise
Cancer Biology
Microbiology and Infectious Disease
Medicine
Epidemiology and Global Health

Research focus
vaccines
cervix cancer
cervix precancer
keratinocyte biology
human papillomavirus
DNA viruses
vaccine immunology

Experimental organism
human
Ivan Topisirovic

Jewish General Hospital, Canada

Expertise
Biochemistry and Chemical Biology
Cancer Biology
Cell Biology

Research focus
mRNA translation
signaling
metabolic regulation
protein quality control

Experimental organism
mouse
human
Samra Turajlic

The Francis Crick Institute, United Kingdom

Expertise
Medicine
Cancer Biology

Research focus
medical oncology
cancer genetics
tumour heterogeneity
melanoma
kidney cancer

Experimental organism
human
Amit Verma

Albert Einstein College of Medicine, United States

Expertise
Medicine
Cancer Biology

Research focus
leukemia
cancer stem cells
myelodysplasia
clonal hematopoiesis
Eric J Wagner

University of Texas Medical Branch at Galveston, United States

Expertise
Chromosomes and Gene Expression
Biochemistry and Chemical Biology
Cancer Biology
Genetics and Genomics

Research focus
RNA biology
transcription
RNA processing
gene expression
Linghua Wang

The University of Texas MD Anderson Cancer Center, United States

Expertise
Cancer Biology
Computational and Systems Biology
Genetics and Genomics
Immunology and Inflammation
Medicine

Research focus
computational biology
cancer immunogenomics
cancer genomics
Jia Wei

Clinical Cancer Institute of Nanjing University, China

Expertise
Cancer Biology
Immunology and Inflammation

Research focus
cancer immunotherapy
immune evasion
tumor immune microenvironment
tumor neoantigen
adoptive cell therapy
tumor-associated macrophages
gastric cancer
immune checkpoints
Jian Xu

University of Texas Southwestern Medical Center, United States

Expertise
Cancer Biology
Chromosomes and Gene Expression
Developmental Biology
Genetics and Genomics
Stem Cells and Regenerative Medicine

Research focus
hematopoiesis
erythropoiesis
myeloid leukemia
epigenetics
transcription regulation
enhancer
metabolism

Experimental organism
human
mouse
Qifeng Yang

Qilu Hospital of Shandong University, China

Expertise
Medicine
Cancer Biology

Research focus
breast cancer
cancer stem cells
metastasis
cancer associated fibroblasts
chemoresistance
Yongliang Yang

Dalian University of Technology, China

Expertise
Medicine
Cancer Biology
Computational and Systems Biology

Research focus
bioinformatics
computational biology
drug discovery
artificial intelligence
Norma Ybarra

Research Institute McGill University Health Center, Canada

Expertise
Cancer Biology
Stem Cells and Regenerative Medicine

Research focus
radiation biology
radiotherapy
cancer cell metabolism
cancer therapies
Keqiang Ye

Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, China

Expertise
Medicine
Cancer Biology
Biochemistry and Chemical Biology
Neuroscience

Research focus
neuroscience
molecular cytobiology
cancer biology
neurodegenerative disease

Experimental organism
mouse
Chunling Yi

Georgetown University, United States

Expertise
Cancer Biology
Cell Biology
Chromosomes and Gene Expression
Genetics and Genomics

Research focus
cancer signaling
mouse models
drug resistance
transcription regulation
Qing Zhang

University of Texas Southwestern Medical Center, United States

Expertise
Cancer Biology
Biochemistry and Chemical Biology

Research focus
CRISPR
cancer metabolism
hypoxia
kidney cancer
breast cancer
epigenetics
post-translational modifications
synthetic lethality
Shengtao Zhou

Sichuan University West China Second University Hospital, China

Expertise
Cancer Biology
Medicine

Research focus
gynecologic oncology
cancer biology
tumor immunology
metabolism
nuclear receptors
systems biology

Experimental organism
human
mouse
Hao Zhu

University of Texas Southwestern Medical Center, United States

Expertise
Cancer Biology
Stem Cells and Regenerative Medicine
Medicine

Research focus
mechanisms of tissue repair and organ regeneration
liver cancer
hepatocellular carcinoma
epigenetics
polyploidy

Experimental organism
human
mouse
Wilbert Zwart

Netherlands Cancer Institute, Netherlands

Expertise
Cancer Biology
Medicine

Research focus
breast cancer
prostate cancer
hormonal regulation
epigenetics
transcription factors
genomic profiling

Experimental organism
human